Stockscreener 앱 받기
11.00
2.05%
-0.23
시간 외 거래:
11.00
전일 마감가:
$11.23
열려 있는:
$11.17
하루 거래량:
1.42M
Relative Volume:
0.52
시가총액:
$1.13B
수익:
$187.64M
순이익/손실:
$-95.00M
주가수익비율:
-11.58
EPS:
-0.95
순현금흐름:
$-69.02M
1주 성능:
+4.96%
1개월 성능:
-2.91%
6개월 성능:
+79.15%
1년 성능:
-9.32%
1일 변동 폭
$10.76
$11.24
1주일 범위
$10.76
$11.99
52주 변동 폭
$5.635
$13.20
Day One Biopharmaceuticals Inc Stock (DAWN) Company Profile
명칭
Day One Biopharmaceuticals Inc
전화
650 484-0899
주소
1800 SIERRA POINT PARKWAY, SUITE 200, BRISBANE
Compare DAWN vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DAWN
Day One Biopharmaceuticals Inc
|
11.00 | 1.15B | 187.64M | -95.00M | -69.02M | -0.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Day One Biopharmaceuticals Inc Stock (DAWN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-13 | 재개 | TD Cowen | Buy |
| 2025-08-19 | 개시 | Piper Sandler | Overweight |
| 2024-10-09 | 재확인 | Needham | Buy |
| 2024-08-01 | 업그레이드 | BofA Securities | Underperform → Buy |
| 2024-04-24 | 재확인 | Needham | Buy |
| 2023-04-25 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2023-02-08 | 개시 | CapitalOne | Overweight |
| 2023-02-03 | 개시 | Oppenheimer | Perform |
| 2022-12-15 | 개시 | H.C. Wainwright | Buy |
| 2022-12-14 | 개시 | Needham | Buy |
| 2022-12-05 | 개시 | Goldman | Buy |
| 2022-12-01 | 개시 | BofA Securities | Buy |
모두보기
Day One Biopharmaceuticals Inc 주식(DAWN)의 최신 뉴스
FMR LLC Reduces Stake in Day One Biopharmaceuticals Inc - GuruFocus
Day One To Report Fourth Quarter and Full-Year 2025 Financial Results Tuesday, February 24, 2026 - GlobeNewswire
Aug Catalysts: Is Day One Biopharmaceuticals Inc a top pick in the sectorMarket Risk Report & Entry Point Strategy Guides - baoquankhu1.vn
Volume Summary: Is Day One Biopharmaceuticals Inc a top pick in the sectorEarnings Growth Summary & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Wall Street Analysts See a 101.08% Upside in Day One Biopharmaceuticals (DAWN): Can the Stock Really Move This High? - Finviz
Will Declining Medical Customers Affect Cigna's Q4 Earnings? - TradingView
AlphaQuest LLC Has $1.30 Million Stock Holdings in Day One Biopharmaceuticals, Inc. $DAWN - MarketBeat
Avoiding Lag: Real-Time Signals in (DAWN) Movement - Stock Traders Daily
Growth Report: How does Day One Biopharmaceuticals Inc compare to its peersPrice Action & Risk Controlled Swing Alerts - baoquankhu1.vn
Day One Biopharmaceuticals (DAWN) Investor Outlook: Unveiling A Potential 111% Upside - DirectorsTalk Interviews
A Look At Day One Biopharmaceuticals (DAWN) Valuation After Recent Share Price Momentum - Yahoo Finance
Day One Biopharmaceuticals (NASDAQ:DAWN) Upgraded to Strong-Buy at Zacks Research - MarketBeat
Will Day One Biopharmaceuticals Inc. face regulatory challenges2025 Historical Comparison & Free AI Powered Buy and Sell Recommendations - mfd.ru
Best Momentum Stocks to Buy for January 27th - Yahoo Finance
New Strong Buy Stocks for January 27th - Yahoo Finance
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Is Day One Biopharmaceuticals Inc a top pick in the sectorQuarterly Profit Summary & Fast Entry High Yield Stock Tips - baoquankhu1.vn
AIGH Capital Management LLC Makes New Investment in Day One Biopharmaceuticals, Inc. $DAWN - MarketBeat
Day One Biopharmaceuticals, Inc (DAWN) Stock Analysis: A Biotech with 90% Upside Potential - DirectorsTalk Interviews
Will Day One Biopharmaceuticals Inc. stock go up in YEARJuly 2025 PreEarnings & Smart Money Movement Alerts - mfd.ru
Assessing Day One Biopharmaceuticals (DAWN) Valuation After Strong OJEMDA Revenue Update And 2026 Growth Outlook - simplywall.st
Discipline and Rules-Based Execution in DAWN Response - Stock Traders Daily
'Follow The Money,' Not The Tariff Noise, Says Expert, Spotlights This New S&P Data Center Cooling Stock Among Top Picks - Sahm
Optimistic Investors Push Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Shares Up 31% But Growth Is Lacking - simplywall.st
Day One Biopharmaceuticals (NASDAQ:DAWN) Stock Price Up 7.6%Time to Buy? - MarketBeat
Day One Biopharmaceuticals Sees Unusually Large Options Volume (NASDAQ:DAWN) - MarketBeat
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Short Interest Up 19.2% in December - MarketBeat
H.C. Wainwright Maintains Buy Rating on Day One Biopharmaceuticals (DAWN), Keeps PT - MSN
Earnings Beat: How does Day One Biopharmaceuticals Inc compare to its peersJuly 2025 Gainers & Low Volatility Stock Recommendations - baoquankhu1.vn
First Week of March 20th Options Trading For Day One Biopharmaceuticals (DAWN) - Nasdaq
Wall Street Analysts Think Day One Biopharmaceuticals (DAWN) Could Surge 107.36%: Read This Before Placing a Bet - sharewise.com
Day One Biopharmaceuticals (DAWN) Is Up 11.7% After Strong OJEMDA 2025 Sales And 2026 OutlookHas The Bull Case Changed? - Sahm
Update Report: Is Day One Biopharmaceuticals Inc a top pick in the sectorQuarterly Risk Review & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Retail Trends: Can Day One Biopharmaceuticals Inc generate free cash flow2025 Big Picture & Fast Entry Momentum Alerts - baoquankhu1.vn
Rally Mode: How geopolitical tensions affect Day One Biopharmaceuticals Inc stockLayoff News & Daily Chart Pattern Signals - Bộ Nội Vụ
Day One Biopharmaceuticals (NASDAQ:DAWN) Trading Down 10.1%What's Next? - MarketBeat
Day One Biopharmaceuticals (NASDAQ:DAWN) Earns Buy Rating from Analysts at TD Cowen - MarketBeat
Day One Biopharmaceuticals (DAWN) Surges 26.7%: Is This an Indication of Further Gains? - Yahoo Finance
A Look At Day One Biopharmaceuticals (DAWN) Valuation After Strong OJEMDA Revenue And 2026 Outlook Updates - Yahoo Finance
Day One Biopharmaceuticals stock initiated with Buy rating at TD Cowen - Investing.com Canada
DAWN: OJEMDA's growth and new pipeline assets set the stage for significant revenue expansion in 2026 - TradingView — Track All Markets
Day One Announces Preliminary 2025 OJEMDA™ Net Product Revenue And Provides 2026 Net Product Revenue Guidance - Sahm
Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap UpTime to Buy? - MarketBeat
Gold Rises Sharply; Lyra Therapeutics Shares Plunge - Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Planet Labs PBC, Day One Biopharmaceuticals, Rxsight, SunOpta And Other Big Stocks Moving Higher On Monday - Benzinga
Day One Biopharmaceuticals stock soars after strong 2025 revenue forecast By Investing.com - Investing.com Canada
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Day One Biopharmaceuticals Reports 172% Year-over-Year Growth in 2025 Net Product Revenue, Projects 2026 Revenue Between $225 Million and $250 Million - Quiver Quantitative
Day One says Ojemda 2026 U.S. net product revenue projected to be $225$250 million - marketscreener.com
Day One Biopharmaceuticals Inc (DAWN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Day One Biopharmaceuticals Inc 주식 (DAWN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| York Charles N II | COO and CFO |
Nov 17 '25 |
Sale |
8.91 |
4,062 |
36,212 |
294,715 |
| Merendino Lauren | Chief Commercial Officer |
Nov 17 '25 |
Sale |
8.91 |
3,726 |
33,216 |
50,809 |
| Bender Jeremy | CHIEF EXECUTIVE OFFICER |
Nov 17 '25 |
Sale |
8.91 |
15,894 |
141,690 |
177,165 |
1.24%
0.19%
자본화:
|
볼륨(24시간):